Variant position: 33 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 781 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human AMEPDRKAAVSHWQQQSYLD SGIHSGATTTAPSLSGKGNPE
Mouse AMEPDRKAAVSHWQQQSYLD SGIHSGATTTAPSLSGKGNPE
Rat AMEPDRKAAVSHWQQQSYLD SGIHSGATTTAPSLSGKGNPE
Bovine AMEPDRKAAVSHWQQQSYLD SGIHSGATTTAPSLSGKGNPE
Xenopus laevis AMEPDRKAAVSHWQQQSYLD SGIHSGATTTAPSLSGKGNPE
Zebrafish AMDPDRKAAVSHWQQQSYLD SGIHSGATTTAPSLSGKGNPE
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
2 – 781 Catenin beta-1
23 – 23 Phosphoserine; by GSK3-beta; alternate
29 – 29 Phosphoserine; by GSK3-beta
33 – 33 Phosphoserine; by GSK3-beta and HIPK2
37 – 37 Phosphoserine; by GSK3-beta and HIPK2
41 – 41 Phosphothreonine; by GSK3-beta
45 – 45 Phosphoserine
49 – 49 N6-acetyllysine
23 – 23 O-linked (GlcNAc) serine; alternate
29 – 29 S -> F. No effect.
Identification of two novel regulated serines in the N-terminus of beta-catenin.
van Noort M.; van de Wetering M.; Clevers H.;
Exp. Cell Res. 276:264-272(2002)
Cited for: PHOSPHORYLATION AT SER-23 AND SER-29 BY GSK3B; PHOSPHORYLATION AT THR-41; MUTAGENESIS OF SER-29; CHARACTERIZATION OF VARIANTS HEPATOCELLULAR CARCINOMA ARG-23; ALA-37 AND ALA-41; CHARACTERIZATION OF VARIANT PTR TYR-33; CHARACTERIZATION OF VARIANT MDB ALA-37; CHARACTERIZATION OF VARIANT DESMOID TUMOR ALA-41; CHARACTERIZATION OF VARIANT HEPATOBLASTOMA ALA-41;
Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6.
Palka-Hamblin H.L.; Gierut J.J.; Bie W.; Brauer P.M.; Zheng Y.; Asara J.M.; Tyner A.L.;
J. Cell Sci. 123:236-245(2010)
Cited for: PHOSPHORYLATION AT TYR-64; TYR-142; TYR-331 AND TYR-333; INTERACTION WITH PTK6; MUTAGENESIS OF TYR-64;
Forkhead Box F2 Suppresses Gastric Cancer through a Novel FOXF2-IRF2BPL-beta-Catenin Signaling Axis.
Higashimori A.; Dong Y.; Zhang Y.; Kang W.; Nakatsu G.; Ng S.S.M.; Arakawa T.; Sung J.J.Y.; Chan F.K.L.; Yu J.;
Cancer Res. 78:1643-1656(2018)
Cited for: INTERACTION WITH IRF2BPL; VARIANT TYR-33;
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.
Morin P.J.; Sparks A.B.; Korinek V.; Barker N.; Clevers H.; Vogelstein B.; Kinzler K.W.;
Cited for: VARIANTS COLORECTAL CANCER TYR-33 AND SER-45 DEL;
A common human skin tumour is caused by activating mutations in beta-catenin.
Chan E.F.; Gat U.; McNiff J.M.; Fuchs E.;
Nat. Genet. 21:410-413(1999)
Cited for: VARIANTS PTR GLY-32; TYR-32; PHE-33; TYR-33; GLU-34; CYS-37; PHE-37 AND ILE-41;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.